Dr. Lin is on staff at CHOC Children's Hospital
Outpatient Clinic, Hyundai Cancer Institute at CHOC Children's
1201 W La Veta Ave
Orange, CA 92868
phone: (714) 509-4348
fax: (714) 509-8699
map & directions
Dr. Carol Lin is a CHOC Children’s Specialist in pediatric hematology/oncology.
Dr. Lin is currently involved in research studies pertaining to Dickkopf-3 (DKK3) protein transfected into osteosarcoma cells inhibit tumorigenesis and metastasis in vivo and in vitro studies, and Prognostic biomarkers in osteosarcoma in determining varying responses to chemotherapy and potential metastasis. She obtained CHOC IRB approval to enroll osteosarcoma patients to obtain diagnostic biopsy tissue.
Dr. Lin is board certified in pediatrics. Prior to joining CHOC Children’s Dr. Lin attended medical school at SUNY Upstate Medical University in Syracuse, New York. She served her residency training in pediatrics at CHOC Children’s and his currently conducting her fellowship in pediatric hematology/oncology at CHOC.
Dr. Lin is fluent in Korean and conversational Spanish. She is affiliated with CHOC Children’s Hyundai Cancer Institute: Cancer Survivorship Symposium.
Carol H. Lin, Yi Guo, Samia Ghaffar, et al. Dkk-3, a secreted Wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma. Sarcoma, vol. 2013, Article ID 147541, doi: 10.1155/2013/147541.
Tao Ji, Carol H. Lin, Lauren S. Krill, et al. Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Molecular Cancer 2013, Vol 12(55).
Maheen Hassan, Carol H. Lin, and Lilibeth Torno. Risk factors for obesity and time frame of weight gain in non-irradiated survivors of pediatric acute lymphoblastic leukemia. Journal of Cancer Therapy 2013, Vol 4(1):124-132.
Carol H. Lin, Chapter 32.2.1. Personalizing your risk profile: Understanding your treatment summary. Handbook of long term care of the childhood cancer survivor. Editors: Lilibeth Torno, Grace A. Mucci. Pending submission 12/2012.
Carol H. Lin, Elyssa Rubin, Lilibeth Torno, Violet Shen, Bang H. Hoang. IRB Protocol: Prognostic biomarkers in osteosarcoma: Varying responses to chemotherapy and potential metastasis. IRB approved 11/2012.